Hypertension DTC Ads Should Attribute Benefits To All Blood Pressure Drugs
Executive Summary
Antihypertensive drug direct-to-consumer advertisements should include a statement that all drugs that lower blood pressure reduce risk of serious cardiovascular outcomes, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said April 27
You may also be interested in...
FDA Encourages Sponsors Of Hypertension Drugs To Promote Their Cardiovascular Benefits
Final guidance allowing class-wide outcomes claims includes suggested language for both advertising and labeling.
Hypertension Labeling Should Say Classes Are All Effective, But Unequally So
Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
Hypertension Labeling Should Say Classes Are All Effective, But Unequally So
Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said